Patients with sacroiliitis showed significantly decreased SPARCC scores after 3 months of TNF-α inhibitor treatment, indicating TNF-α inhibitor therapy is effective in treating axSpA patients. The gene discussed is TNF; the disease is Sacroiliac arthritis.